Wilson Sonsini Goodrich & Rosati has advised ABL Bio. ABL Bio has announced the signing of an equity investment agreement valued at KRW 22 billion with...
ABL Bio Announces Equity Investment Agreement with Lilly
ABL Bio’s Worldwide Licensing Agreement with GSK
Wilson Sonsini Goodrich & Rosati advised ABL Bio on the transaction. Simmons & Simmons has advised GSK. ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company...
ABL Bio’s License Agreement with SANOFI
Wilson Sonsini Goodrich & Rosati advised ABL on the deal. ABL Bio, Inc., a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced...


























